Análisis Argos
GRDN
GRDNCara
Guardian Pharmacy Services, Inc. · Healthcare
US$ 42.00
precio al 2026-07-04
Valor justo Argos*
US$ 24–30
vs. su valor justo
55% por encima
Score Argos
64/100
LA RESPUESTA
El mercado le pide crezca 25.9% al año — más de lo que ha demostrado (15.3%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
Retorno sobre el capital alto (33%).
Tiene más caja que deuda: balance fuerte.
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
VALOR2/6FUTURO3/6PASADO4/6SALUD6/6DIVIDENDO2/6
El Iris de calidad
VALOR2/6FUTURO3/6PASADO4/6SALUD6/6DIVIDENDO2/6
ValorCerca de su valor justo
FuturoCrecimiento moderado
PasadoFundamentales sólidos y sostenidos
SaludBalance fuerte, deuda controlada
DividendoRetorno al accionista moderado
Score Argos64de 100Cara
Ingresos18%
US$ 1.5 B
Margen operativo220%
6.1%
Flujo de caja libre100%
US$ 0.1 B
Deuda neta
US$ -0 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 2.7B
P/E54x
EV/EBITDA23.6x
FCF yield3%
ROIC33.4%
Margen operativo6.1%
Crecim. ingresos+17.9%/año
Piotroski F6/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

businesswire.com · 22 jun
Guardian Pharmacy Services, Inc. Announces Leadership Transitions
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that Kendall Forbes, who has served as Executive Vice President of Sales & Operations since 2004, has decided to retire, effective as of July 1, 2026. Upon Mr. Forbes's retirement, David Morris, currently Executive Vice President and Chief Financial Officer of Guardian will assume the role of Chief Operating Officer. In connection with Mr. Morris' new role, Will Mudd, Senior Vice President, Finance, has b.
zacks.com · 8 jun
Guardian Pharmacy Services, Inc. (GRDN) Hit a 52 Week High, Can the Run Continue?
Guardian Pharmacy (GRDN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
seekingalpha.com · 13 may
Guardian Pharmacy Services, Inc. (GRDN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Guardian Pharmacy Services, Inc. (GRDN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
marketbeat.com · 10 may
Guardian Pharmacy Services Q1 Earnings Call Highlights
Guardian Pharmacy Services NYSE: GRDN reported what executives described as a solid first quarter of 2026, with management saying the company successfully navigated the initial implementation of the Inflation Reduction Act's new framework while maintaining its full-year revenue outlook and raising adjusted EBITDA guidance.
zacks.com · 6 may
Guardian Pharmacy Services (GRDN) Q1 Earnings and Revenues Surpass Estimates
Guardian Pharmacy Services (GRDN) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.21 per share a year ago.
seekingalpha.com · 6 may
Guardian Pharmacy Services, Inc. (GRDN) Q1 2026 Earnings Call Transcript
Guardian Pharmacy Services, Inc. (GRDN) Q1 2026 Earnings Call Transcript
businesswire.com · 6 may
Guardian Pharmacy Services Reports First Quarter 2026 Financial Results; Updates Full-Year Guidance
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation's leading long-term care ("LTC") pharmacy services companies, announced today its financial results for the first quarter ended March 31, 2026. The Company also updated its full-year guidance. First Quarter Financial Results Revenue of $336.6 million, up 2% year-over-year. Residents served ended the quarter at approximately 207,000, up 10% year-over-year. Net Income of $13.5 million, compared to $9.3 mill.
zacks.com · 30 abr
Stevanato Group (STVN) Reports Next Week: Wall Street Expects Earnings Growth
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.